

Economic analysis using base-case estimates

	Usual care	STS HM	STS HH	TM during office hours
Central estimates of HRs used as input				
Mortality HR	1.000	1.074	0.780	0.779
HF-related hospitalisation HR	1.000	1.045	0.778	0.966
All-cause hospitalisation HR	1.000	1.173	0.977	0.761
Treatment costs assumed per month (£)	27	119	179	175
Survival results (undiscounted)				
1 year (%)	72.14	71.45	75.34	75.38
5 years (%)	33.75	33.43	35.25	35.27
Life expectancy over 30 years (years)	4.71	4.67	4.91	4.91
Difference in life expectancy vs usual care (years)	0.00	-0.04	0.20	0.20
Cost results (£)				
Discounted cost of usual care	491	343	362	362
Discounted cost of treatment	0	632	978	1173
Discounted cost of HF-related hospitalisations	4187	4169	4257	4348
Discounted cost of other hospitalisations	3800	3858	4007	3803
Total costs	8478	9001	9604	9686
Difference in costs from usual care (£)				
Discounted cost of usual care	0	-148	-129	-129
Discounted cost of treatment	0	632	978	1173
Discounted cost of HF-related hospitalisations	0	-19	70	161
Discounted cost of other hospitalisations	0	57	207	3
Total difference in costs	0	523	1126	1207
Overall cost rank (1 = lowest cost)	1	2	3	4
Discounted QALY results				
QALYs with no hospitalisation decrement	2.5748	2.5509	2.6834	2.6848
HF-related hospitalisation decrement	-0.1611	-0.1604	-0.1638	-0.1673
Total discounted QALYs	2.4137	2.3905	2.5196	2.5175

	Usual care	STS HM	STS HH	TM during office hours
<i>Difference in QALYs from usual care</i>				
QALYs with no hospitalisation decrement	0.0000	-0.0239	0.1086	0.1100
HF-related hospitalisation decrement	0.0000	0.0007	-0.0027	-0.0062
Total difference in discounted QALYs	0.0000	-0.0232	0.1059	0.1038
Total discounted QALYs rank (1 = highest)	3	4	1	2
Probabilistic ICER vs usual care (£/QALY)		Dominated	10,629	11,633
Probabilistic sequential ICER (£/QALY)		Dominated	10,629 ^a	Dominated
<i>Uncertainty analyses using net benefit at £20,000 per QALY</i>				
Probability that strategy is most cost-effective (%)	3	19	40	38
Expected total costs from PSA (£)	8478	9001	9604	9686
Expected total QALYs from PSA	2.4137	2.3905	2.5196	2.5175
Expected net benefit from PSA (£)	39,795	38,809	40,788	40,664
Difference from usual care costs (£)	0	523	1126	1207
Difference from usual care QALYs	0.0000	-0.0232	0.1059	0.1038
Difference from usual care net benefit (£)	0	-986.75	993	869
Net benefit rank (1 = highest)	3	4	1	2
Overall EVPI per patient at ICER of £20,000 per QALY (£)	829			
Population EVPI (£)	45,411,538			
a Last strategy in the cost-effectiveness frontier.				

Economic analysis using data from predictive distributions

	Usual care	STS HM	STS HH	TM during office hours
<i>Central estimates of HRs used as input</i>				
Mortality HR	1.000	1.180	0.849	0.843
HF-related hospitalisation HR	1.000	1.063	0.790	0.982
All-cause hospitalisation HR	1.000	1.302	1.074	0.835
Treatment costs assumed per month (£)	27	119	179	175
<i>Survival results (undiscounted)</i>				
1 year (%)	72.14	70.61	74.58	74.66
5 years (%)	33.75	33.04	34.89	34.93
Life expectancy over 30 years (years)	4.710	4.614	4.862	4.867
Difference in life expectancy vs usual care (years)	-	-0.100	0.151	0.157

	Usual care	STS HM	STS HH	TM during office hours
Cost results (£)				
Discounted cost of usual care	491	339	358	359
Discounted cost of treatment	0	627	972	1166
Discounted cost of HF-related hospitalisations	4187	4130	4221	4316
Discounted cost of other hospitalisations	3800	3869	4023	3811
Total costs	8478	8965	9574	9652
Difference in costs from usual care (£)				
Discounted cost of usual care	0	-152	-132	-132
Discounted cost of treatment	0	627	972	1166
Discounted cost of HF-related hospitalisations	0	-57	33	129
Discounted cost of other hospitalisations	0	69	223	11
Total difference in costs	0	487	1096	1174
Overall cost rank (1 = lowest cost)	1	2	3	4
Discounted QALY results				
QALYs with no hospitalisation decrement	2.5748	2.5223	2.6575	2.6605
HF-related hospitalisation decrement	-0.1611	-0.1589	-0.1624	-0.1661
Total discounted QALYs	2.4137	2.3633	2.4950	2.4944
Difference in QALYs from usual care				
QALYs with no hospitalisation decrement	0.0000	-0.0525	0.0827	0.0857
HF-related hospitalisation decrement	0.0000	0.0022	-0.0013	-0.0050
Total difference in discounted QALYs	0.0000	-0.0504	0.0814	0.0808
Total discounted QALYs rank (1 = highest)	3	4	1	2
Probabilistic ICER vs usual care (£/QALY)		Dominated	13,473	14,532
Probabilistic sequential ICER (£/QALY)		Dominated	13,473 ^a	Dominated
Uncertainty analyses using net benefit at £20,000 per QALY				
Probability that strategy is most cost-effective (%)	7	20	37	37
Expected total costs from PSA (£)	8478	8965	9574	9652
Expected total QALYs from PSA	2.4137	2.3633	2.4950	2.4944
Expected net benefit from PSA (£)	39,795	38,301	40,327	40,237
Difference from usual care costs (£)	0	487	1096	1174
Difference from usual care QALYs	0.0000	-0.0504	0.0814	0.0808
Difference from usual care net benefit (£)	0	-1494.07	531	442
Net benefit rank (1 = highest)	3	4	1	2
Overall EVPI per patient at ICER of £20,000 per QALY (£)	1871			
Population EVPI (£)	102,490,939			

a Last strategy in the cost-effectiveness frontier.

Economic analysis using data excluding the Home-HF study⁶⁷

	Usual care	STS HM	STS HH	TM during office hours
Central estimates of HRs used as input				
Mortality HR	1.000	1.007	0.757	0.627
HF-related hospitalisation HR	1.000	1.042	0.766	0.872
All-cause hospitalisation HR	1.000	1.134	0.969	0.678
Treatment costs assumed per month (£)	27	119	179	175
Survival results (undiscounted)				
1 year (%)	72.14	72.14	75.67	77.63
5 years (%)	33.75	33.75	35.40	36.32
Life expectancy over 30 years (years)	4.710	4.710	4.930	5.052
Difference in life expectancy vs usual care (years)	–	–0.0003	0.2200	0.3420
Cost results (£)				
Discounted cost of usual care	491	346	363	373
Discounted cost of treatment	0	635	981	1191
Discounted cost of HF-related hospitalisations	4187	4206	4269	4426
Discounted cost of other hospitalisations	3800	3873	4021	3879
Total costs	8478	9060	9635	9870
Difference in costs from usual care (£)				
Discounted cost of usual care	0	–144	–127	–118
Discounted cost of treatment	0	635	981	1191
Discounted cost of HF-related hospitalisations	0	18	82	239
Discounted cost of other hospitalisations	0	73	221	79
Total difference in costs	0	582	1157	1392
Overall cost rank (1 = lowest cost)	1	2	3	4
Discounted QALY results				
QALYs with no hospitalisation decrement	2.5748	2.5747	2.6949	2.7612
HF-related hospitalisation decrement	–0.1611	–0.1619	–0.1643	–0.1703
Total discounted QALYs	2.4137	2.4128	2.5306	2.5908
Difference in QALYs from usual care				
QALYs with no hospitalisation decrement	0.0000	–0.0002	0.1200	0.1864
HF-related hospitalisation decrement	0.0000	–0.0007	–0.0032	–0.0092
Total difference in discounted QALYs	0.0000	–0.0009	0.1169	0.1772
Total discounted QALYs rank (1 = highest)	3	4	2	1
Probabilistic ICER vs usual care (£/QALY)		Dominated	9897	7854
Probabilistic sequential ICER (£/QALY)		Dominated	Extendedly dominated	7854 ^a

	Usual care	STS HM	STS HH	TM during office hours
Uncertainty analyses using net benefit at £20,000 per QALY				
Probability that strategy is most cost-effective (%)	0	6	16	78
Expected total costs from PSA (£)	8478	9060	9635	9870
Expected total QALYs from PSA	2.4137	2.4128	2.5306	2.5908
Expected net benefit from PSA (£)	39,795	39,196	40,976	41,947
Difference from usual care costs (£)	0	582	1157	1392
Difference from usual care QALYs	0.0000	-0.0009	0.1169	0.1772
Difference from usual care net benefit (£)	0	-599.54	1181	2152
Net benefit rank (1 = highest)	3	4	2	1
Overall EVPI per patient at ICER of £20,000 per QALY (£)	175			
Population EVPI (£)	9,586,271			
a Last strategy in the cost-effectiveness frontier.				

Economic analysis using data from predictive distributions excluding the Home-HF study⁶⁷

	Usual care	STS HM	STS HH	TM during office hours
Central estimates of HRs used as input				
Mortality HR	1.000	1.032	0.776	0.642
HF-related hospitalisation HR	1.000	1.058	0.778	0.883
All-cause hospitalisation HR	1.000	1.235	1.048	0.731
Treatment costs assumed per month (£)	27	119	179	175
Survival results (undiscounted)				
1 year (%)	72.14	71.89	75.44	77.44
5 years (%)	33.75	33.63	35.30	36.23
Life expectancy over 30 years (years)	4.71	4.69	4.92	5.04
Difference in life expectancy vs usual care (years)	0.00	-0.02	0.21	0.33
Cost results (£)				
Discounted cost of usual care	491	345	362	372
Discounted cost of treatment	0	634	979	1190
Discounted cost of HF-related hospitalisations	4187	4200	4262	4422
Discounted cost of other hospitalisations	3800	3909	4055	3901
Total costs	8478	9087	9658	9884
Difference in costs from usual care (£)				
Discounted cost of usual care	0	-145	-128	-119
Discounted cost of treatment	0	634	979	1190

	Usual care	STS HM	STS HH	TM during office hours
Discounted cost of HF-related hospitalisations	0	12	75	234
Discounted cost of other hospitalisations	0	108	255	101
Total difference in costs	0	609	1180	1406
Overall cost rank (1 = lowest cost)	1	2	3	4
Discounted QALY results				
QALYs with no hospitalisation decrement	2.5748	2.5659	2.6870	2.7548
HF-related hospitalisation decrement	-0.1611	-0.1616	-0.1640	-0.1701
Total discounted QALYs	2.4137	2.4043	2.5230	2.5847
Difference in QALYs from usual care				
QALYs with no hospitalisation decrement	0.0000	-0.0089	0.1122	0.1800
HF-related hospitalisation decrement	0.0000	-0.0004	-0.0029	-0.0090
Total difference in discounted QALYs	0.0000	-0.0093	0.1093	0.1710
Total discounted QALYs rank (1 = highest)	3	4	2	1
Probabilistic ICER vs usual care (£/QALY)		Dominated	10,798	8223
Probabilistic sequential ICER (£/QALY)		Dominated	Extendedly dominated	8223 ^a
Uncertainty analyses using net benefit at £20,000 per QALY				
Probability that strategy is most cost-effective (%)	1	8	23	68
Expected total costs from PSA (£)	8478	9087	9658	9884
Expected total QALYs from PSA	2.4137	2.4043	2.5230	2.5847
Expected net benefit from PSA (£)	39,795	39,000	40,801	41,809
Difference from usual care costs (£)	0	609	1180	1406
Difference from usual care QALYs	0.0000	-0.0093	0.1093	0.1710
Difference from usual care net benefit (£)	0	-795.73	1006	2014
Net benefit rank (1 = highest)	3	4	2	1
Overall EVPI per patient at ICER of £20,000 per QALY (£)	473			
Population EVPI (£)	25,910,322			

^a Last strategy in the cost-effectiveness frontier.